3/7
05:33 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $15.00 price target on the stock.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $15.00 price target on the stock.
3/5
07:43 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
3/4
07:07 pm
acrs
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
3/4
08:05 am
acrs
Aclaris Therapeutics to Participate in Two March Healthcare Conferences [Yahoo! Finance]
Medium
Report
Aclaris Therapeutics to Participate in Two March Healthcare Conferences [Yahoo! Finance]
3/4
07:00 am
acrs
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
2/28
07:47 am
acrs
Seborrheic Keratosis Global Clinical Trials Market Review 2025, Competitive Analysis of Aclaris Therapeutics, DermBiont, EpiPharm, BioLineRx, DermResearch, LEO Foundation, maxingvest, Novartis [Yahoo! Finance]
Low
Report
Seborrheic Keratosis Global Clinical Trials Market Review 2025, Competitive Analysis of Aclaris Therapeutics, DermBiont, EpiPharm, BioLineRx, DermResearch, LEO Foundation, maxingvest, Novartis [Yahoo! Finance]
2/27
11:33 pm
acrs
Aclaris Therapeutics plans $300M mixed shelf offering [Seeking Alpha]
Low
Report
Aclaris Therapeutics plans $300M mixed shelf offering [Seeking Alpha]
2/27
06:59 am
acrs
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Medium
Report
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
2/14
09:09 pm
acrs
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis [Yahoo! Finance]
2/14
09:09 pm
acrs
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc [Yahoo! Finance]
Low
Report
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc [Yahoo! Finance]
2/14
09:09 pm
acrs
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
2/12
08:57 am
acrs
Lakewood-Amedex Names Douglas Manion, M.D., FRCP (C), as Chairman of the Board of Directors [Yahoo! Finance]
Medium
Report
Lakewood-Amedex Names Douglas Manion, M.D., FRCP (C), as Chairman of the Board of Directors [Yahoo! Finance]
2/12
07:22 am
acrs
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 [Yahoo! Finance]
Medium
Report
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 [Yahoo! Finance]
2/12
06:50 am
acrs
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Low
Report
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
2/8
01:36 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/1
05:58 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
1/31
02:09 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
1/30
04:53 pm
acrs
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board [Yahoo! Finance]
Medium
Report
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board [Yahoo! Finance]
1/30
04:01 pm
acrs
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
Medium
Report
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
1/6
04:30 pm
acrs
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/23
10:33 am
acrs
Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls [Yahoo! Finance]
Low
Report
Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls [Yahoo! Finance]
12/23
07:27 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock.
12/19
04:57 pm
acrs
Aclaris Therapeutics files to sell 35.56M shares of common stock by selling shareholders [Seeking Alpha]
Low
Report
Aclaris Therapeutics files to sell 35.56M shares of common stock by selling shareholders [Seeking Alpha]